A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)

Launched by MERCK SHARP & DOHME LLC · May 20, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment called sacituzumab tirumotecan (MK-2870) to see how well it works alone or in combination with chemotherapy for certain advanced gastrointestinal cancers. The types of cancers being studied include colorectal cancer, pancreatic ductal adenocarcinoma, and biliary tract cancer that cannot be removed by surgery or has spread to other parts of the body. The main goals of the study are to check how safe the treatment is and to find out how many participants experience a reduction or complete disappearance of their cancer.

To be eligible for this trial, participants must have one of the specific types of cancer mentioned, must have already received previous cancer treatments, and should have recovered from any side effects of those treatments. Participants can expect to be closely monitored throughout the study to assess their health and how their cancer responds to the treatment. This trial is currently recruiting and is open to people aged 65 and older, regardless of gender. If you or a loved one is considering participation, it’s important to discuss any medical history with the research team to ensure eligibility.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• The main inclusion criteria include but are not limited to the following:
• * Has one of the following cancers:
• • Unresectable or metastatic colorectal cancer
• • Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)
• • Advanced and/or unresectable biliary tract cancer (BTC)
• • Has received prior therapy for the cancer
• • Has recovered from any side effects due to previous cancer treatment
• Exclusion Criteria:
• The main exclusion criteria include but are not limited to the following:
• • History of severe eye disease
• • Received prior systemic anticancer therapy including investigational agents within 4 weeks before starting study intervention
• • History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

Trial Officials